VictoryShares US Discovery Enhanced Volatility Wtd ETF CSF
51.03 USD +0.14 (+0.28%)
At closeApr 23, 2025, 4:00 PM EDT
51.00 Day range 51.39
46.65 52-week range 60.63
- YTD
- -7.02%
- 1 year
- +3.34%
- Market cap
- 30.72M
- P/E ratio
- 16.42
- YTD return
- -7.02%
- 1-year return
- +3.34%
- Volume
- 17.10K
- Avg volume
- 2.19K
- Open
- 51.34
- Previous close
- 50.89
- Day's range
- 51.00 – 51.39
- 52-week range
- 46.65 – 60.63
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 56.81
- 200-day average
- 52.70
About VictoryShares US Discovery Enhanced Volatility Wtd ETF
The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory U.S. Small Cap 500 Long/Cash Volatility Weighted Index. The index identifies the 500 largest U.S. companies with market capitalizations of less than $3 billion measured at the time the index's constituent securities are determined.
News
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease 
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study 
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests 
Cerenome Launches CNSide® CSF Molecular Profile Tests 
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients 
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t 
Chime Scholars Foundation Announces 2026–2027 Cohort 
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform 
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
Your note
Sign in to keep a note on CSF — it syncs with the Stock Master app.